BB102 for advanced solid tumors that have not responded to treatment
Part of Cancer clinical trials.
This trial studies a new drug called BB102 that targets a specific protein (FGF19/FGFR4) found on some cancer cells. It is for people with advanced solid tumors, especially liver cancer, who have run out of standard treatment options. The goal is to see if the drug is safe and helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumors (like liver cancer) that have not responded to or cannot be treated with standard therapies.
- For the expansion part of the study, your tumor must test positive for FGF19 or FGFR4 proteins.
- You must be able to take care of yourself (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- You cannot have had certain other treatments (like chemotherapy, targeted therapy, or immunotherapy) within the past 4 weeks.
- You cannot have serious heart, lung, or liver problems, or active infections that require IV antibiotics.
- You must not be pregnant or breastfeeding, and if you could become pregnant, you must use effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
This trial tests a new drug called ABL103 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
This trial tests a new drug called BB102 for people with liver cancer (HCC) that has grown after at least one previous treatment. The drug targets a specific protein (FGF19) that may be fueling the cancer, and doctors want to see if it can shrink tumors or slow the disease.
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.